STOCK TITAN
  1. Home
  2. News
  3. NTRA

Natera Inc - NTRA STOCK NEWS

Welcome to our dedicated news page for Natera (Ticker: NTRA), a resource for investors and traders seeking the latest updates and insights on Natera.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Natera's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Natera's position in the market.

News
Natera Reports Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
Natera, Inc. (NTRA) reports strong financial results for Q4 2023, showing significant revenue growth and test volume increases. The company achieved total revenues of $311.1 million in Q4 2023, up 43.2% from the previous year, with product revenues growing by 44.3%. Natera processed approximately 2,496,100 tests in 2023, a 20.8% increase from 2022. The company's gross margins improved to 51.4% in Q4 2023. Natera expects 2024 revenue of $1.32 billion-$1.35 billion and continues to focus on innovation and growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.98%
Tags
earnings
-
News
Natera Announces Next Phase of CareDx Patent Infringement Litigation Seeking Royalty For All Ongoing And Future AlloSure Tests
Rhea-AI Summary
Natera, Inc. (NTRA) progresses in patent infringement litigation against CareDx with a $96.3 million jury verdict in lost profits and past royalties. The U.S. District Court will decide on future royalties for ongoing AlloSure testing. Discovery and briefing to continue till summer 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.66%
Tags
none
-
News
Medicare Extends Coverage of Natera’s Signatera™ MRD Test to Ovarian Cancer and Neoadjuvant Breast Cancer
Rhea-AI Summary
Natera, Inc. (NTRA) announces that its Signatera MRD test has met coverage requirements from CMS in new indications for ovarian and breast cancer. The test has shown promising results in detecting recurrence early and predicting therapy response, potentially improving outcomes for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.29%
Tags
none
News
Natera Announces Fourth Quarter and Fiscal 2023 Earnings Conference Call
Rhea-AI Summary
Natera, Inc. (NTRA) to release Q4 and year-end 2023 financial results on Feb. 28, 2024. Conference call and webcast to follow. Details provided for investors and traders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.57%
Tags
earnings
-
News
New Study Validates Signatera™ in Endometrial Cancer
Rhea-AI Summary
Natera, Inc. (NASDAQ: NTRA) announced a study validating its MRD test, Signatera, in endometrial cancer. The study showed that patients who tested Signatera MRD-positive experienced significantly higher rates of recurrence, making Signatera a powerful post-surgical biomarker of recurrence risk for patients with endometrial cancer. The potential for Signatera to redefine adjuvant treatment pathways in endometrial cancer was demonstrated in the study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.61%
Tags
none
-
News
New Publication Demonstrates Signatera’s Ability to Risk Stratify and Detect Recurrence Early in Resected Stage I-II Lung Cancer
Rhea-AI Summary
Natera, Inc. (NTRA) announced a new study demonstrating the effectiveness of its Signatera MRD test in detecting recurrence early in patients with resected stage I-II non-small cell lung cancer. The study showed that clinical management was altered in 100% of patients with a Signatera positive result, highlighting the potential of this test in risk stratification. With NSCLC accounting for 81% of all lung cancer diagnoses in the U.S., this study has significant implications for patient care and cancer management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.62%
Tags
none
News
Jury Rules in Favor of Natera in Patent Infringement Lawsuit Against CareDx; Awards $96.3 Million in Damages to Natera in Lost Profits and Past Royalties
Rhea-AI Summary
Natera, Inc. (NTRA) has won a patent infringement case against CareDx, Inc., with the jury awarding Natera $83.7 million in lost profits and $12.6 million in past royalties. The jury also found that all asserted claims of Natera's patents are valid and provided an advisory verdict that all asserted claims are valid under 35 U.S.C. Sec. 101. Further proceedings will determine whether CareDx's future sales of new versions of AlloSeq and AlloSure also infringe Natera's patents.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.48%
Tags
none
-
News
CareDx Issues Statement in Patent Infringement Case
Rhea-AI Summary
CareDx, Inc. (Nasdaq: CDNA) has been found to have not infringed on Natera, Inc.'s patent 10,655,180 but was found to have infringed on patent 11,111,544. The District of Delaware jury awarded Natera damages of $83,679,521 in lost profits and $12,535,500 in past royalties for alleged infringement by AlloSure from September 2021 through August 2023. CareDx intends to seek judicial review of the verdict. The decision does not impact patient or physician access to CareDx's current offerings, including AlloSure or AlloMap.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Nature Medicine Publishes Two Studies Highlighting Signatera’s Clinical Utility in Patients with Gastrointestinal Malignancies
Rhea-AI Summary
Natera, Inc. (NASDAQ: NTRA) announced the publication of two new studies in Nature Medicine evaluating Natera’s personalized and tumor-informed molecular residual disease (MRD) test, Signatera.™ The first study, AMPLIFY-201, evaluated the ELI-002 cancer vaccine and enrolled 25 patients with solid tumors. Results showed that 21 patients had Signatera-positive status after locoregional treatment, and tumor biomarker responses were observed in 84% of patients. The study highlights the potential utility of ctDNA as a reliable surrogate biomarker for treatment efficacy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.51%
Tags
none
News
Natera Acquires Reproductive Health Assets from Invitae
Rhea-AI Summary
Natera, Inc. (NTRA) has acquired certain assets from Invitae (NVTA) related to non-invasive prenatal screening and carrier screening business. The upfront payment to Invitae was $10 million, with potential milestone payments totaling $42.5 million. Invitae will transition its customers to Natera. Natera CEO, Steve Chapman, expressed commitment to providing excellent service and supporting additional patients and providers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.08%
Tags
acquisition
Stock NTRA logo
Natera Inc

Nasdaq:NTRA

NTRA Rankings

#750 Ranked by Market Cap
#3235 Ranked by Stock Gains
N/A Ranked by Dividends

NTRA Stock Data

11.41B
116.45M
4.1%
96.19%
5.17%
Medical Laboratories
Health Care and Social Assistance
Link
United States
Austin

About NTRA

natera is a san carlos, ca-based company that is driven by a passion for elevating the science and utility of prenatal testing. the advent of the information age has created a paradigm shift in the fields of computing and informatics. surprisingly, medical diagnostics have been slow to integrate these advances into genetic testing. until natera. from conception to delivery, natera is pioneering next-generation accuracy and reliability in preconception and prenatal genetic testing services, enabling couples to be informed about their pregnancy each step of the way. the company offers a wide range of tests from preimplantation genetic diagnosis (pgd) for ivf to breakthrough advances in the field of non-invasive prenatal testing (nipt). using advances from the human genome project and powered by sophisticated proprietary bioinformatic algorithms, natera’s comprehensive portfolio of tests, proven science, and experienced genetic counseling services deliver the most accurate results in the